Caribou Biosciences Stock

cariboubio.comHealthcare / BioTech & PharmaFounded: 2011Funding to Date: $41.55MM

Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.

Register To Buy and Sell Shares

For more details on financing and valuation for Caribou Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Caribou Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Caribou Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Barbara McClung
Chief Legal Officer and Corporate Secretary
Timothy Herpin Ph.D
Chief Business Officer
Chris Fuller
Vice President, Informatics
Jennifer Doudna Ph.D
Co-Founder & Scientific Advisor
Steven Kanner Ph.D
Chief Scientific Officer
Edny Inui
Director, Business Development
James Berger
Rachel Haurwitz Ph.D
Co-Founder, Board Member, President and Chief Executive Officer
Martin Jinek Ph.D
Co-Founder & Scientific Advisor
Scott Gradia Ph.D
Vice President of Platform Research

Board Members

Philip Austin
Anterra Capital
Robert Weisskoff Ph.D
Natalie Sacks MD
Rachel Haurwitz Ph.D

News Highlights

Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells
Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering wi
Updated on: Feb 25, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.